Pfizer Derivative Assets - Fair Value decreased by 31.7% to $41.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 91.6%, from $487.00M to $41.00M. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates higher potential cash inflows and a stronger position in the derivative market.
This represents the total fair value of derivative financial instruments that are in a net asset position at the reporti...
Standard disclosure for all banks with significant trading or derivative portfolios.
derivative_assets_fair_value| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $35.00M | $246.00M | $532.00M | $739.00M | $1.50B | $715.00M | $422.00M | $333.00M | $251.00M | $281.00M | $104.00M | $487.00M | $42.00M | $60.00M | $41.00M |
| QoQ Change | — | +602.9% | +116.3% | +38.9% | +103.0% | -52.3% | -41.0% | -21.1% | -24.6% | +12.0% | -63.0% | +368.3% | -91.4% | +42.9% | -31.7% |
| YoY Change | — | — | — | >999% | +509.8% | +34.4% | -42.9% | -77.8% | -64.9% | -33.4% | -68.8% | +94.0% | -85.1% | -42.3% | -91.6% |